This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be used to generate participant-derived tumor models that will serve as a resource to better understand hereditary cancers and develop new efficient therapies.
Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.
Individuals 18 years of age or older on the day of signing informed consent.
Individuals with solid tumor malignancy with germline or somatic cancer-associated mutations and/or Individuals with a family history or personal history of cancer.
Surgical resection
None
Adults with solid tumor malignancies and germline or somatic mutations for cancer and/or a personal or family history of cancer
Case-control
Prospective
Blood Sample
Procedure/SurgeryObtained at the time of non-study related routine blood draw.
Tissue Sample
Procedure/SurgeryObtained at the time of non-study related routine biopsy or surgical procedure.
Excess fluid Sample
Procedure/SurgeryObtained at the time of non-study related routine biopsy, surgical procedure, paracentesis, or thoracentesis procedure.
Medical Chart Review
Other interventionDemographic, clinical, and pathologic information will be extracted from the medical record
Develop participant-derived tumor models of hereditary cancers
Participant-derived models may include (but are not limited to) xenografts (PDX), organoids (PDO), and cell lines (PDCLs). These models recapitulate the biology and tissue context of the original tumors from which they are derived and can be used to study effective therapeutic strategies.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
